Press Releases

License and Commercialization Agreement with Illumina

BRISBANE, Calif., May 09, 2018 (GLOBE NEWSWIRE) -- CareDx (NASDAQ:CDNA), today announced that, as reported in its Current Report on Form 8-K filed with the Securities Exchange Commission on May 8, 2018, it entered into a License and Commercialization Agreement with Illumina, Inc., which provides CareDx with worldwide distribution, development and commercialization rights to Illumina’s next generation sequencing (NGS) product line for use in transplantation diagnostic testing.

Beginning on June 1, 2018, CareDx will be the exclusive worldwide distributor of Illumina’s TruSight HLA Sequencing Panels and associated Assign HLA software for use in transplantation diagnostic testing. In addition, CareDx will be granted the exclusive right to develop and commercialize additional transplant NGS products using the Illumina platform, which will be branded as AlloSeq HLA, AlloSeq BMT and AlloSeq cfDNA.

Under the agreement, CareDx made a one-time payment to Illumina and will pay royalties on sales of future commercialized products. CareDx is committed to complete development and commercialization of the future products, and has agreed to minimum purchase commitments from Illumina through 2023. Illumina will provide transition and support services to CareDx.

“CareDx is uniquely positioned to provide genomic information to transplant patients to enable personalized medicine in this high need, high cost population.  We continue to deliver on our promise to bring next generation sequencing solutions to the transplant clinic,” said Peter Maag, Chief Executive Officer of CareDx.

About CareDx

CareDx, Inc., headquartered in Brisbane, California, is a molecular diagnostics company focused on the discovery, development and commercialization of clinically differentiated, high-value solutions for transplant recipients. CareDx offers products across the transplant testing continuum, including AlloMap® and AlloSure® for post-transplant surveillance and Olerup SSP®, Olerup QTYPE, and Olerup SBT™ for pre-transplant HLA testing.

For more information, please visit: www.CareDx.com.

Forward Looking Statements

This press release contains forward-looking statements about our business, research, development and commercialization efforts, including statements regarding the development and commercialization of future NGS products and our ability to bring next generation sequencing solutions to the transplant clinic. These forward-looking statements are based upon information that is currently available to us and our current expectations, speak only as of the date hereof, and are subject to numerous risks and uncertainties, including risks associated with successful research, development and planned commercialization of our technologies, that are described in our filings with the SEC, including the Annual Report on Form 10-K for the fiscal year ended December 31, 2017 filed by us with the SEC on March 22, 2018.  Any of these may cause our actual results, performance or achievements to differ materially and adversely from those anticipated or implied by our forward-looking statements. We expressly disclaim any obligation, except as required by law, or undertaking to update or revise any such forward-looking statements.

CONTACTS:

CareDx, Inc.
Sasha King
Chief Commercial Officer
415-287-2393
sking@caredx.com

Investor Relations
David Clair
Integrated Corporate Relations, Inc.
646-277-1266
david.clair@icrinc.com

 

 

Source: CareDx, Inc.